Table 1.
Clinical and histopathological parameters in NY-ESO-1 positive and negative primary cutaneous melanomas.
| Parameter | Subgroup | Number of patients (%) | NY-ESO-1 (+) | NY-ESO-1 (−) |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Gender | Male | 31 (40) | 8 (26) | 23 (74) |
| Female | 47 (60) | 8 (17) | 39 (83) | |
|
| ||||
| Skin phototype | I | 1 (2) | 0 (0) | 1 (100) |
| II | 35 (56) | 7 (20) | 28 (80) | |
| III | 22 (35) | 5 (22) | 17 (78) | |
| IV | 4 (6) | 2 (50) | 2 (50) | |
| V | 2 (3) | 0 (0) | 2 (100) | |
| VI | 1 (2) | 0 (0) | 1 (100) | |
|
| ||||
| Median age (years) | 78 | 55.2 | 58.3 | |
|
| ||||
| Location | Extremity | 28 (35) | 6 (21) | 22 (79) |
| Trunk | 29 (37) | 6 (21) | 23 (79) | |
| Head and neck | 14 (18) | 1 (7) | 13 (93) | |
| Acral (Hand and foot) | 8 (11) | 3 (37.5) | 5 (62.5) | |
|
| ||||
| Melanoma subtype | Superficial spreading | 31 (39) | 2 (6)* | 29 (94)* |
| Nodular | 26 (33) | 6 (23) | 20 (77) | |
| Lentigo maligna | 7 (9) | 3 (43) | 4 (57) | |
| Acral lentiginous | 8 (10) | 3 (37.5) | 5 (62.5) | |
| Unclassified | 7 (9) | 2 (29) | 5 (71) | |
|
| ||||
| Ulceration | Present | 16 (20) | 5 (31) | 11 (69) |
| Absent | 63 (80) | 11 (17) | 52 (83) | |
|
| ||||
| Breslow# | ≤1.0 mm | 24 (30) | 2 (8) | 22 (92) |
| 1.01–2.0 mm | 23 (29) | 3 (13) | 20 (87) | |
| 2.01–4.0 mm | 6 (8) | 3 (50) | 3 (50) | |
| >4.0 mm | 26 (33) | 8 (31) | 18 (69) | |
|
| ||||
| Sentinel lymph node | Positive | 2 (11) | 0 (0) | 2 (100) |
| Negative | 16 (89) | 4 (25) | 12 (75) | |
|
| ||||
| Follow-up | Disease-free | 37 (54) | 10 (27) | 27 (73) |
| Alive with metastases | 14 (21) | 2 (14) | 12 (86) | |
| Dead of melanoma | 14 (21) | 2 (14) | 12 (86) | |
| Lost | 3 (4) | 2 (67) | 1 (33) | |
NY-ESO-1 (+): NY-ESO-1 positive; NY-ESO-1 (−): NY-ESO-1 negative; * P < 0.02 for superficial spreading compared to other primary tumor types;
# P value was not significant when Breslow index was analyzed as a categorical variable (groups); however, P = 0.017 when Breslow index was analyzed as a continous variable.